| Name | Title | Contact Details |
|---|---|---|
Anindita Sinha |
Vice President of Commercial | Profile |
Gianine Esposito |
Senior Vice President and Chief Human Resources Officer | Profile |
Martin Buckland |
Vice President, US New Products | Profile |
Pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart.
Canada’s Global Life Sciences Venture / Partenaire d’affaires en sciences de la vie au Canada #lifesciences #biotech #sante
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
RPS Pharmacy is an affiliate of Millenium Pharmaceuticals and as such, we are committed to quality healthcare with an honest approach that values patient privacy and security. All information provided to us is legally protected under the doctor-patient